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FlavivirusThe structure of recombinant domain III of the envelope protein (rED3) of yellow fever virus (YFV),
containing the major neutralization site, was determined using NMR spectroscopy. The amino acid sequence
and structure of the YFV-rED3 shows differences from ED3s of other mosquito-borne ﬂaviviruses; in
particular, the partially surface-exposed BC loop where methionine-304 and valine-324 were identiﬁed as
being critical for the structure of the loop. Variations in the structure and surface chemistry of ED3 between
ﬂaviviruses affect neutralization sites and may affect host cell receptor interactions and play a role in the
observed variations in viral pathogenesis and tissue tropism.
© 2009 Elsevier Inc. All rights reserved.Introduction
Yellow fever virus (YFV) is an arthropod-borne virus belonging to
the family Flaviviridae, genus Flavivirus. Most ﬂaviviruses are typically
transmitted by either mosquitoes or ticks, and include major human
pathogens such as YFV, dengue virus (DENV types 1–4), West Nile
virus (WNV), Japanese encephalitis virus (JEV), and tick-borne
encephalitis virus (TBEV). Yellow fever is an acute viral disease that
causes hemorrhagic fever and jaundice. The virus is transmitted
between humans by the Aedes aegypti mosquito and about 200,000
cases are reported annually, including 30,000 deaths. Because no
treatment or cure exists for yellow fever, there is great interest in
developing strategies to control the disease. Unlike other mosquito-
borne ﬂaviviruses, YFV has a tropism for the liver and causes a
viscerotropic disease whereas many other mosquito-borne ﬂavi-
viruses have a tropism for the brain, or in the case of the DEN viruses
they target cells of reticuloendothelial origin.ute of Molecular Medicine, The
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.G. Gorenstein).
olecular Medicine, University
SA.
niversity,Atlanta,GA30322,USA.
ll rights reserved.The YFV genome is an 11 kb single-stranded positive-sense RNA
genome coding for a polyprotein, which is post- and co-translationally
processed into three structural proteins and seven non-structural
proteins. The largest of the structural proteins, the envelope (E)
protein, is the major component of the virion surface. It is the primary
immunogen and plays a central role in receptor binding and
membrane fusion (Heinz and Allison, 2003). The structure of the
ectodomain (the soluble N-terminal portion, consisting of 395
residues) of the E protein of TBEV was determined by x-ray
crystallography (Rey et al., 1995). Based on this structure, three
distinct structural domains, domains I, II, and III, have been identiﬁed
in the ectodomain. This structure has been conﬁrmed by x-ray
crystallographic studies of other ﬂaviviruses, including DENV1 (Nayak
et al., 2009), DENV2 (Modis et al., 2003), DENV3 (Modis et al., 2005),
and WNV (Kanai et al., 2006; Nybakken et al., 2006). Domains I and II
lie parallel to the virion surface in the mature, pre-fusion form. They
contain the fusion peptide and the hinge region, both involved in the
low-pH induced conformational change observed upon fusion and
entry into the cell, and the N-linked glycosylation site(s) (Rey et al.,
1995). Domain III (ED3) is involved in receptor binding and contains
epitopes critical for type-speciﬁc neutralization of the virus (i.e., those
neutralization epitopes that distinguish each ﬂavivirus, e.g. YFV from
DENV2) (Chu et al., 2005; Crill and Roehrig, 2001). The major
neutralization epitopes ofWNV (Beasley and Barrett, 2002; Nybakken
et al., 2005; Sánchez et al., 2005), YFV (Ryman et al., 1998), DENV2
13Rapid Communication(Hiramatsu et al., 1996; Roehrig et al., 1988; Gromowski and Barrett,
2007; Sukupolvi-Petty et al., 2007), TBEV (Mandl et al., 1989;
Holzmann et al., 1997), and JEV (Cecilia and Gould, 1991; Wu and
Lin, 2001; Lin and Wu, 2003; Wu et al., 1997, 2003, 2004; Goncalvez
et al., 2008) have all been mapped to ED3.
Cryoelectron microscopic reconstructions of several ﬂaviviruses
indicate that the E protein is arranged as dimers parallel to the virion
surface, such that ED3 projects slightly above the viral surface (Kuhn
et al., 2002; Mukhopadhyay et al., 2003). Interactions between ﬁve
ED3 subunits at the virion 5-fold axes of symmetry form pores on theFig. 1. Ribbon diagrams of rED3 of YFV and WNV. β-Sheets 1–3 are colored yellow, orange,
green. (A and B) Two orthogonal views of the NMR-derived YF rED3 backbone atom structurevirion surface where cell receptors may bind. NMR-derived solution
structures of the JEV (Wu et al., 2003), WNV (Volk et al., 2004), Omsk
hemorrhagic fever virus (OHFV (Volk et al., 2006)), Langat virus
(LGTV (Mukherjee et al., 2006)), and DENV4 (Volk et al., 2007b) rED3
illustrate an overall similar structural fold for this domain of these
ﬂaviviruses, with speciﬁc differences between those viruses trans-
mitted by mosquito or tick vectors. In this study, we have solved the
solution structure of rED3 of wild-type strain Asibi of YFV and
demonstrate that it is markedly different from ED3 of other mosquito-
borne ﬂaviviruses that have been solved.and magenta, respectively, and the disulﬁde bridge between C300 and C330 is colored
s. Surface loop structure of (C and D) YF rED3 and (E and F)WN rED3 (Volk et al., 2004).
Table 1
Summary of NMR structure constraints and statistics.
Total restraints 1833
NOE restraints 1278
Intra-residue 609
Sequential 319
Medium range 59
Long range 291
TALOS phi/psi dihedral restraints 170
Omega dihedral restraints 111
Chirality restraints 274
Structural statistics
NOE violationsN0.5 Å 3±1
NOE violationsN0.3 Å 13±2
Dihedral angle violationN20° 0
Dihedral angle violationN10° 2±1
RMSD from ideal geometry
Bond lengths (Å) 0.013
Bond angles (°) 2.1
Restraint error RMSD
Distance restraints (Å) 0.019±0.071
Dihedral restraints (°) 0.54±1.51
Atomic pairwise RMSD
Backbone atoms 1.38±0.44
All heavy atoms 1.59±0.41
Ramachandran statistics
Most favored regions (%) 81.8
Additionally allowed regions (%) 16.9
Generously allowed regions (%) 1.1
Disallowed regions (%) 0.2
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Quality of the NMR structure
The 20ﬁnal structures of YFV-rED3 in the ensemble (Figs. 1A and B)
had low molecular and restraint energy penalties. The structure
presented here is well deﬁned, as shown by the RMSD values and
restraint violations listed in Table 1. Theﬁnal structures, determined in
an automated fashion, had 13±2 distance violations over 0.3 Å, 3±
1 violation over 0.5 Å and 2±1 dihedral angle violations over 10°,
and no dihedral angle violations over 20° (Table 1). Thus, 99.9% of the
NMR-derived restraints ﬁt the structures determined. Most of the
violations occur in four or fewer of the twenty structures, although six
are nearly always violated. The violations occur because the NOE
interactions and cutoff distances were set in an automated fashion
into distance spins based on cross-peak volumes, disregarding
confounding effects such as amide proton exchange rates, equivalent
geminal methyl groups, ambiguous NOE assignments, and differing
spin–spin relaxation rates. The RMSD on the distance restraint error
was 0.019±0.071 Å, and the RMSD on dihedral angle error was
0.54±1.51°. The structural ensemble has an average pairwise
backbone atom RMSD of 1.38±0.44 Å and an average pairwise
heavy atom RMSD of 1.59±0.41 Å. The program PROCHECK was used
to analyze the quality of the ﬁnal ensemble. Analysis of the non-
glycine, non-proline residues indicated that 98.7% of these residues are
in the two most favored regions of a Ramachandran plot. Speciﬁcally,
81.8% of the residues are in the most favored regions, 16.9% are in the
additionally allowed regions, 1.1% are in the generously allowed
regions, and 0.2% are in the disallowed regions.Notes to Table 2:
Asterisks (⁎) indicate highly conserved residues and hashes (#) indicate residues with g
labeled underneath using TBEV (Rey et al., 1995) nomenclature. The number of the ﬁrst am
each ﬂavivirus. Those without available full length E genes sequences are left blank. Bioch
alignment.
aICTV abbreviations used are as follows: yellow fever virus=YFV, Edge Hill virus=EHV, Ju
Entebbe bat virus=ENTV, Yokose virus=YOKV, West Nile virus=WNV, St Louis enceph
Bussuquara virus=BSQV, Iguape virus=IGUV, Zika virus=ZIKAV, Spondweni virus=SPOV
Royal Farm virus=RFV, Kadam virus=KADV, Meaban virus=MEAV, Modoc virus=MO
virus=RBV.Structural details of the NMR ensemble
The overall structure ensemble of YFV ED3 determined by NMR
(Figs. 1A and B; Table 2, all amino acid numbers in the text refer to
amino acid number in the speciﬁc viral E protein being discussed,
unless otherwise deﬁned) is similar to that reported for the ED3 of
other ﬂaviviruses, including DENV1 (Nayak et al., 2009), DENV2
(Modis et al., 2003), DENV3 (Modis et al., 2005), DENV4 (Volk et al.,
2007b), JEV (Wu et al., 2003), LGTV (Mukherjee et al., 2006), OHFV
(Volk et al., 2006), TBEV (Rey et al., 1995), and WNV (Volk et al.,
2004). The YFV-rED3 structure has nine β-strands in three β-sheets
arranged in an IgG-like β-barrel conﬁguration. The ﬁrst β-sheet
(yellow) contains β-strands A from Ser305 to Asp312, β-strand B from
Val318 to Lys323, β-strand D from Ile348 to Leu349, and β-strand E
from Glu362 to Asn368. The second β-sheet (orange) is formed by
only two short β-strands, Cx and Dx, encompassing residues Cys330-
Lys331 and Ile355-Ala356, respectively. The last β-sheet (magenta) is
comprised of β-strand C from Val334-Ala337, β-strand F fromGly372-
Val378 and β-strand G from Leu385-Lys391. Both the overall global
fold and the secondary structures of YFV-rED3 are grossly similar to
the structures reported for mosquito-borne DENV1, DENV2, DENV3,
DENV4, JEV, and WNV rED3, although small differences in the lengths
of β-sheets do exist. However, the major difference between the YFV
ED3 structure and other ﬂavivirus structures is found at the surface-
exposed loops; particularly in the BC loop. This difference is directly
related to the addition of Pro325 in YFV (found in no other ﬂavivirus;
see Figs. 1C and D), and the presence of relatively small, non-aromatic
residues at positions Met304 and Val324 of YFV ED3 (Figs. 1C and D
and Table 2) compared to other mosquito-borne ﬂaviviruses (see
WNV ED3 in Figs. 1E and F).
The residues comprising the ﬂavivirus BC loops differ signiﬁcantly
in mosquito and tick vectors and between ﬂavivirus complexes
(Table 2). All of the mosquito-borne ﬂaviviruses, excluding the YFV
complex, contain a conserved tyrosine immediately before the BC
loop (amino acid position 329 for WNV in Table 2 and Figs. 1E and F),
which has been shown to be essential for viability of WNV (Zhang, S.
and Beasley, D.W.C., unpublished data) and presumably plays a role in
stabilizing the ED3 protein fold while some of the tick-borne viruses
have a phenylalanine substitution in place of the tyrosine. The
phenylalanine at amino acid position 305 in the alignment (equiva-
lent to F309 in WNV and M304 in YFV), which is packed closely with
the tyrosine at position 329 in the WNV ED3 structure, is also
conserved in these viruses. In contrast, YFV-rED3, as well as other YFV
complex viruses (Wesslesbron [WSLV], Sepik [SEPV], Saboya [SABV],
Jugra [JUGV], Edge Hill [EHV], Yokose [YOKV], and Entebbe Bat viruses
[ENTV]), contain a methionine at position 304 and a valine at position
324. Immediately following the valine at 324, the BC loop of YFV both
starts and ends with a proline (amino acids 325 and 329), whereas all
other ﬂaviviruses have BC loops ending with a proline only. The
proline present at position 325 in the YFV E protein removes the need
for a tyrosine or phenylalanine at position 324 by forcing the BC loop
to start turning towards the next beta strand. The smaller sizes of
Met304, relative to a phenylalanine, and Val324, relative to either a
tyrosine or a phenylalanine, allow the length of the BC loop to be
smaller in YFV and related viruses compared to the other mosquito-
borne ﬂaviviruses.roup-speciﬁc differences. β-Strands are indicated with underlined residues and are
ino acid of ED3 for each ﬂavivirus is shown in superscript to the right of the name of
emically similar amino acids are the same color to allow easier understanding of the
gra virus=JUGV, Saboya virus=SABV, Wesselsbron virus=WSLV, Sepik virus=SEPV,
alitis virus=SLEV, Ntaya virus=NATV, Rocio virus=ROCV, Kokobera virus=KOKV,
, dengue virus=DENV, Kedougou virus=KEDV, tick-borne encephalitis virus=TBEV,
DV, Apoi virus=APOIV, Montana myotis leukoencephalitis virus=MMLV, Rio Bravo
Table 2
Alignment of ﬂavivirus ED3 proteins from mosquito-, tick-, and non-vector-borne ﬂaviviruses.
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Fig. 2.NeutralizingepitopesonED3of yellow fever (YF), dengue-2 (DEN2), Japanese encephalitis (JE), tick-borne encephalitis (TBE), andWestNile (WN)viruses. Reddots identify amino
acids recognized by type-speciﬁc monoclonal antibodies.
16 Rapid CommunicationThese differences in loops are unique in the YFV complex viruses
and would be predicted to contribute to differences in antigenicity
and differences in the individual amino acids that constitute the
major type-speciﬁc neutralization epitopes on different ﬂaviviruses.
In particular, the major neutralization epitope in YFV involves the
serine at residue 305 and proline at residue 325 (Ryman et al., 1998),
while it is the lysine at residue 307, the threonine at residue 330, and
threonine at residue 332 for WNV (Beasley and Barrett, 2002;
Nybakken et al., 2005); the lysine at residue 305 and proline at
residue 384 for DENV2 (Hiramatsu et al., 1996; Gromowski and
Barrett, 2007; Sukupolvi-Petty et al., 2007); the glycine at residue
302, glutamine or glycine at residue 306, serine or arginine at residue
331, aspartic acid at residue 332, and glycine at residue 333 for JEV
(Cecilia and Gould, 1991; Wu and Lin, 2001; Lin and Wu, 2003;
Goncalvez et al., 2008), and the glycine at residue 368, tyrosine at
residue 384, and serine at residue 389 for TBEV (Mandl et al., 1989;
Holzmann et al., 1990). Based on this information, Fig. 2 shows that
the location of the type-speciﬁc epitopes associated with neutraliza-
tion for WNV, JEV, TBEV, DENV2 and YFV viruses are not in identical
locations on ED3. (i.e., YFV: 305 and 325 [B-C loop], DENV2: 305 and
284 [F-G loop], WNV: 310 and 332 [B-C loop], JEV: 302, 306, 331, 332,
and 333 [B-C loop], TBEV: 384 and 389). Thus, different surface-
exposed loops on ED3 of different ﬂaviviruses are important for
neutralizing epitopes.
Discussion
Identiﬁcation of structural and/or amino acid differences in ED3
has revealed differences in the critical type-speciﬁc neutralization
epitopes that is leading to a greater understanding of how each
ﬂavivirus is distinguished immunologically. The newly determined
structure of the ED3 of YFV, representing a major ﬂavivirusserocomplex not previously subjected to detailed structural
analysis, was compared with the structure of the ED3s of other
ﬂaviviruses.
The structure of the ED3 of YFV differs from the structures of other
mosquito-borne ﬂaviviruses; in particular, the surface-exposed loops,
especially the BC loop, are different (see Figs. 1C–F). In YFV, the BC
loop is one amino acid shorter than in the mosquito-borne and non-
vector-borne viruses, but the same length as most tick-borne viruses.
Although the function of the BC loop is unknown, it contains themajor
neutralization determinant for YFV (residue 325), WNV (residue 332;
Beasley and Barrett, 2002; Nybakken et al., 2005), and JEV (residue
333; Wu and Lin, 2001). The structures in Figs. 1C–F suggest that not
all ﬂavivirus type-speciﬁc neutralization epitopes are in analogous
positions, which supports the hypothesis that the function of the BC
loop may be different for at least YFV, WNV, and JEV. In addition, a
nearby loop, the FG loop, located on the same surface of ED3, has been
shown to be the major neutralization determinant for TBEV and
DENV2 (see Fig. 2) and is involved in vector-speciﬁc receptor binding
of DENV2 (Hung et al., 2004). Like the BC loop, the FG loop is longer in
most mosquito-borne viruses than the tick-borne viruses. The
differences in this loop, in combination with other variations in
surface chemistry, most likely contribute to the diversity in antige-
nicity, and possibly receptor binding and host speciﬁcity and tissue
tropism.
The overall structure of the ED3s of most mosquito-borne
ﬂaviviruses, including DENV1 (Nayak et al., 2009), DENV2 (Modis
et al., 2003), DENV4 (Volk et al., 2007b), WNV (Volk et al., 2004), and
JEV (Wu et al., 2003) are very similar, and comparison of the amino
acid sequences reveals several motifs unique to these virus complexes.
The same is true of the tick-borne viruses such as TBEV (Rey et al.,
1995), LGTV (Mukherjee et al., 2006), and OHFV (Volk et al., 2006)
(see Table 2). In contrast, the structure of the YFV ED3 has several
17Rapid Communicationunique differences when compared with other mosquito-borne
ﬂaviviruses; in particular, the surface-exposed BC loop is shorter in
YFV than any other mosquito-borne virus. These differences are
reﬂected in the amino acid sequence of this region, and due to a high
level of similarity of the amino acid sequence of ED3 betweenmembers
of the YFV complex (see Table 2), these structural differences can be
expected to occur in other members of the YFV complex.
Materials and methods
Protein expression and puriﬁcation
Uniformly 15N,13C-labeled human YFV-rED3 protein (Asibi
strain) encompassing residues (Ser288-Lys398) was expressed
using the pET-15b vector (Novagen), with an added methionine
residue on the N-terminus but lacking the N-terminal His-tag
sequence encoded in that plasmid. The cells were lysed using the
native lysis buffer and centrifuged to obtain the YFV-rED3 protein
along with the crude cell debris in the pellet. The pellet is then
dissolved in denaturing lysis buffer containing 6 M guanidine
hydrochloride to solubilize the protein. The insoluble cell debris is
removed by centrifugation. The guanidine HCl in the supernatant
was then removed by dialysis (6×1:2000 dilution). The expressed
protein was ﬁltered through an Amicon centrifugal ﬁlter concen-
trator with a 50 kDa molecular weight cutoff to remove proteins
with higher molecular weight. Size exclusion chromatography was
performed using Sephadex G-75 beads to further purify the protein.
Centricon concentrators with a 3 kDa cutoff membrane were used
for the ﬁnal concentration step and to remove low-molecular
weight impurities, as well as to exchange the material into the ﬁnal
NMR buffer.
NMR spectroscopy and the generation of NMR restraints
The NMR samples contained 0.1–0.4 mM protein in 50 mM
deuterated Tris (pH 5.8), 50 mM NaCl, 1 mM NaN3 in 90% H2O, and
10% D2O. NMR experiments were performed at 25 °C on Varian Inova
750 MHz (UTMB) or 600 MHz (with cold probe, Rice University)
spectrometers with triple resonance probes. The 13C and 15N
dimensions were referenced indirectly using frequency ratios.
Sequence-speciﬁc backbone assignments were obtained using the
2D 1H, 15N-HSQC, 3D HNCACB, 3D CBCA(CO)NH and 3D HNCO
experiments as described previously (Volk et al., 2007a). Non-
aromatic side chain assignments were obtained using the HCCH-
TOCSY, TOCSY-[1H,15N]-HSQC, H(C)CH-TOCSY, H(CCO)NH, and C(CO)
NH experiments as described previously (Volk et al., 2007a). Aromatic
proton assignments were obtained from the (HB)CB(CGCD)HD and
(HB)CB(CGCDCE)HE experiments. A NOESY-[1H,15N]-HSQC experi-
ment provided several missing side chain assignments as described
previously (Volk et al., 2007a). Stereo-speciﬁc assignments for some
of the side chain protons were obtained after initial rounds of
structure calculations using ambiguous restraints. The NMR spectra
were processed in VNMRJ (Varian, Inc.) or Felix2000 (Felix, Inc.)
software. SANEwas used to facilitate the assignment of the 15N-edited
or 13C-edited NOE cross-peaks and for the generation of restraints as
described previously (Volk et al., 2007a). Chemical shifts, distance
cutoffs, and contribution cutoffs were used within the program. The
NMR restraints were separated into four bins, based on the NOESY
cross-peak volumes from which they were derived, with upper
distance limits of 2.5, 3.5, 4.5, and 6.0 Å for all NOE data. The 1833
NOE-based restraints (see Table 1) consist of 609 intra-residue, 319
sequential, 59 medium-range, and 291 long-range distance restraints.
TALOS was used to derive 170 phi/psi dihedral angle restraints based
on the chemical shifts of the amino acids. Additional angular restraints
for the omega angles and correct chiralities were generated within
AMBER6.0.Molecular dynamics calculations
One hundred random structures were generated by annealing the
protein at 700 K, obtaining the coordinates every 5 ps and minimizing
the structures obtained. The structures were then subjected to r-MD
using dihedral angle restraints (Table 1) followed by the application of
all restraints at 300 K. Finally, the structures were energy minimized
for 2000 steps. Twenty structures with the lowest restraint penalties
were then chosen for the structural ensemble. The SANDER module
within AMBER6.0 (Case et al., 1999) was used for all NMR structure
calculations, and MIDAS (Ferrin et al., 1988) and MOLMOL (Koradi,
Billeter, and Wuthrich, 1996) were used to visualize the structures.
Coordinates for the ensemble of NMR structures of YFV-rED3 have
been deposited with the Protein Data Bank (PDB ID 2JQM) and the
chemical shifts have been deposited with the BMRB (Volk et al.,
2007a; accession code 15034).
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